Ignyta Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Ignyta, Inc. (RXDX) (“Ignyta”), a biotechnology company focused on precision medicine in oncology, today announced the closing of its previously announced underwritten public offering of 14.375 million shares of its common stock at a price to the public of $6.15 per share, which includes 1.875 million additional shares of common stock issued upon the exercise in full of the underwriters’ option to purchase additional shares. The aggregate gross proceeds from this offering are approximately $88.4 million, before deducting the underwriting discounts and commissions and estimated offering expenses.